4D Molecular Therapeutics (FDMT) Net Cash Flow (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Net Cash Flow data on file, last reported at $12.2 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $12.2 million, up 177.46% year-over-year; the trailing twelve-month figure through Mar 2026 was -$61.0 million (up 57.04% YoY), and the FY2025 annual result was -$89.1 million, up 10.7% from the prior year.
• Net Cash Flow climbed to $12.2 million in Q1 2026 per FDMT's latest filing, from $11.7 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $157.7 million in Q2 2023 and troughed at -$86.5 million in Q2 2024.
• A 5-year average of -$4.7 million and a median of -$5.2 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow jumped 859.1% in 2023, then slumped 1779.37% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$55.9 million in 2022, then jumped by 52.51% to -$26.6 million in 2023, then plunged by 43.78% to -$38.2 million in 2024, then surged by 130.59% to $11.7 million in 2025, then grew by 4.8% to $12.2 million in 2026.
• Business Quant data shows FDMT's Net Cash Flow at $12.2 million in Q1 2026, $11.7 million in Q4 2025, and -$28.6 million in Q3 2025.